IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

- 1. (previously presented) A derivative formed between hyaluronic acid and at least one heterocyclic compound selected from purine or pyrimidine, said derivative having at least one bond of a ionic type between said acid and said at least one heterocyclic compound.
- 2. (original) The derivative according to Claim 1, characterized in that said hyaluronic acid is hyaluronic acid of high molecular weight.
- 3. (original) The derivative according to Claim 2, characterized in that said hyaluronic acid has a molecular weight of between 400 000 and 4 million dalton.
- 4. (original) The derivative according to Claim 3, characterized in that said hyaluronic acid has a molecular weight of between 800 000 and 3.5 million dalton.
- 5. (original) The derivative according to Claim 4, characterized in that said hyaluronic acid has a molecular weight of between 1.5 and 3 million dalton.
- 6. (original) The derivative according to Claim 1, characterized in that said hyaluronic acid is hyaluronic acid of low molecular weight.
- 7. (currently amended) <u>A derivative formed between hyaluronic acid and at least one</u> The derivative according to Claim 1, characterized in that said-heterocyclic compound [[is]] selected from the group consisting of adenine, guanine, thymine, cytosine, uracyl, 5,6 dihydrouracyl, 1-methyluracyl, 3-methyluracyl, 5-hydroxymethyluracyl, 2- thiouracyl, N^4 -acetylcytosine, 3-methylcytosine, 5-methylcytosine, 5- hydroxymethylcytosine, 4-methyladenine, 2-methyladenine, 7-methyladenine, N^6 -methyladenine, N^6 -dimethyladenine, N^6 -methyladenine, $N^$

methylguanine, and N², N²-dimethylguanine; said derivative having at least one ionic bond between said hyaluronic acid and said at least one heterocyclic compound.

- 8. (currently amended) A derivative formed between hyaluronic acid and at least one The derivative according to Claim 1, characterized in that said heterocyclic compound [[is]] selected from the group consisting of adenine, guanine, thymine, and cytosine; said derivative having at least one ionic bond between said hyaluronic acid and said at least one heterocyclic compound.
- 9. (previously presented) The derivative according to Claim 1, characterized in that said bond of a ionic type is obtained between said acid and at least two of said heterocyclic compounds that are the same as or different from one another.
- 10. (currently amended) The derivative according to Claim [[1]] 8, characterized in that it is guanine hyaluronate.
- 11. (previously presented) The derivative according to Claim 1, characterized in that it is adenine hyaluronate.
- 12. (previously presented) The derivative according to Claim 1, characterized in that it is associated with at least one organic compound.
- 13. (previously presented) The derivative according to Claim 12, characterized in that said organic compound is selected from the group consisting of natural amino acids, their oligomers and polymers.
- 14. (original) The derivative according to Claim 13, characterized in that it is guanine hyaluronate, polylysine.

- 15. (original) The derivative according to Claim 13, characterized in that it is adenine hyaluronate, polylysine.
- 16. (original) The derivative according to Claim 1, characterized in that it is cross-linked.
- 17. (original) The derivative according to Claim 16, characterized in that said cross-linking involves at least one hydroxyl group and/or at least one carboxyl group present on said hyaluronic acid.
- 18. (original) The derivative according to Claim 16, characterized in that said cross-linking is obtained with phospene.
- 19. (currently amended) A process for the preparation of a derivative <u>formed</u> [[from]] between hyaluronic acid and at least one heterocyclic compound according to Claim 1, <u>the process comprising-characterized in that reacting at least one carboxyl group of the hyaluronic acid or a salt thereof-reacts</u> with at least one <u>amine group of the heterocyclic compound in free or salified form to form at least one ionic bond.</u>
- 20. (currently amended) A process for the preparation of a derivative formed between hyaluronic acid and at least one heterocyclic compound, and associated with at least one organic compound according to Claim 12, the process comprising characterized in that associating said derivative or a salt thereof reacts with at least one organic compound in free or salified form.
- 21. (currently amended) A method of using a derivative according to Claim 1, the method comprising applying characterized in that said derivative is used as a cosmetic to a subject.

- 22. (currently amended) A method of using a derivative according to Claim 1, the method comprising administering characterized in that said derivative is used as a pharmaceutical to a subject.
- 23. (currently amended) <u>A cosmetic Cosmetic or pharmaceutical composition[[s]]</u> comprising <u>said derivative having at least one ionic bond between said hyaluronic acid and said at least one heterocyclic [[the]] compound[[s]] referred to in Claim 1.</u>
- 24. (currently amended) <u>A cosmetic Cosmetic or pharmaceutical composition[[s]]</u> comprising <u>said derivative having at least one ionic bond between said hyaluronic acid and said at least one heterocyclic compound, and associated with at least one organic [[the]] compound[[s]] referred to in Claim 12.</u>
- 25. (currently amended) A method of using the composition[[s]] referred to in Claim 23, the method comprising providing characterized in that said derivative is used as a cosmetic and/or pharmaceutical to a subject.
- 26. (currently amended) A method of using the composition[[s]] referred to in Claim 24, the method comprising providing characterized in that said derivative is used as a cosmetic and/or pharmaceutical to a subject.
- 27. (previously presented) The derivative according to Claim 12, characterized in that said organic compound is a peptide.